Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) with EGFR mutations often develops resistance to tyrosine kinase inhibitors (TKIs) due to mutations like T790M.
• While osimertinib targets T790M mutations, acquired C797S resistance necessitates novel therapeutic approaches.
• There is an urgent need for new strategies to treat T790M-positive NSCLC.

Purpose of the Study:

• To investigate the potential antitumor effects of wighteone, a natural compound, against NSCLC with T790M mutations.
• To elucidate the mechanism of action of wighteone in T790M-positive NSCLC cells.

Main Methods:

• Established a Ba/F3 cell line with EGFR L858R/T790M mutation.
• Utilized the Ba/F3 EGFR L858R/T790M cell line and the human NCI-H1975 NSCLC cell line (EGFR L858R/T790M).
• Assessed wighteone's effects on cell proliferation, EGFR signaling, cell cycle, and apoptosis.

Main Results:

• Wighteone significantly inhibited NSCLC cell proliferation.
• The compound suppressed the EGFR signaling pathway.
• Wighteone induced cell cycle redistribution and promoted apoptosis in cancer cells.

Conclusions:

• Wighteone demonstrates significant antitumor activity against NSCLC cells harboring T790M mutations.
• The findings suggest wighteone warrants further investigation as a potential therapeutic agent for T790M-positive NSCLC.
• Wighteone may offer a novel treatment strategy for patients resistant to current EGFR-TKIs.